BioSpace News Archive

AlzeCure Pharma AB announced that the company’s presentation at the Alzheimer’s conference AD/PD 2022, about the research platform NeuroRestore and its potential role in mitochondrial function, is now available in its entirety on the company’s website.

ECMOHO Limited today announced that on March 16, 2022, the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) approved the Company’s request to transfer the listing of the Company’s American Depositary Shares (the “ADSs”) from the Nasdaq Global Market to the Nasdaq Capital Market.

Canopy, the Intelligent Care Platform for oncology, announced it has raised $13 million in funding led by GSR Ventures, with participation from Samsung Next, UpWest, and other industry leaders and executives, such as Geoff Calkins, and Chris Mansi.

Tetra Bio-Pharma Inc. received the response letter for a Type C meeting with the United States Food and Drug Administration (FDA) for its inhaled cannabinoid-based product, QIXLEEF™.

Evelo Biosciences, Inc. (Nasdaq:EVLO), today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 24, 2022 to report its fourth quarter and full year 2021 financial results and discuss business highlights.

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.

Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, today announced the first patient has been dosed in Encore, the Company’s open-label extension (OLE) study for food allergy patients who completed participation in Harmony, its Phase 1/2 study of ADP101.

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the fourth quarter and full year ended December 31, 2021.

Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, will provide a regulatory update on CLN-081 during a webinar being held Monday, March 28, 2022, at 4:30 p.m. ET.

KKR, a leading global investment firm, announced the closing of its previously announced investment in Biosynth Carbosynth, an innovative life sciences reagents, custom synthesis and manufacturing services company, as well as Biosynth Carbosynth’s acquisition of vivitide, a global provider of custom peptides and antibodies for the life sciences and biotech industry.